𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy

✍ Scribed by James N. Ingle; Dr. Douglass C. Tormey; Joan M. Bull; Richard M. Simon


Publisher
John Wiley and Sons
Year
1977
Tongue
English
Weight
602 KB
Volume
39
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Combination chemotherapy for breast canc
✍ Rosalba Rodriguez-Kraul; Gabriel N. Hortobagyi; Aman U. Buzdar; George R. Blumen πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 595 KB

Seventy-nine patients with metastatic breast cancer underwent examination of their bone marrow as part of their staging workup. Thirty-one (3%) showed no evidence of bone marrow involvement (BM-); 48 (61%) were found to have bone marrow metastases (BM+). Both groups of patients were treated with int

The effect of combined androgen blockade
✍ Terrence Diamond; Joanne Campbell; Carl Bryant; William Lynch πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 2 views

## BACKGROUND. Androgen receptor blocking agents have become an established form of therapy for men with disseminated prostate carcinoma. The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities (BMD) in men with disseminated prostate carcinoma treat

The effect of hypoxia on acquired drug r
✍ R. Kalra; A-M. Jones; J. Kirk; G. E. Adams; I. J. Stratford πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 French βš– 646 KB

## Abstract Prolonged hypoxia induced transient drug resistance in Chinese hamster lung fibroblasts. Previously hypoxic cells were resistant to adriamycin and resistant to etoposide. Complete recovery of etoposide sensitivity was observed following re‐aeration for 24 hr. A change in P‐glycoprotein

Effects of ERBB2 amplicon size and genom
✍ Larry E. Morrison; Susan S. Jewell; Lydia Usha; Beth A. Blondin; Ruta D. Rao; Bi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 168 KB

## Abstract Trastuzumab is widely used for advanced breast cancer patients with __ERBB2__‐amplified tumors. Nevertheless, over half of these patients do not have an objective response. One reason may be altered expression of genes that might compensate for __ERBB2__ inhibition. We previously mapped